Foghorn Therapeutics Inc. / Fundamentals
Income statement
- Net revenue
€20.86M - Cost of goods sold
€776.73K - Gross profit
€20.09M - SG&A expenses
€23.67M - R&D expenses
€75.70M - EBITDA
-€73.78M - D&A
€2.78M - EBIT
-€79.28M - Interest expenses
€0.00 - EBT
-€65.07M - Tax expenses
€0.00 - Net income
-€65.07M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€2.77M - Changes in working capital
-€18.19M - Operating cash flow
-€78.10M - Capex
€723.22K - Other investing cash flow
€0.00 - Net investing cash flow
€20.89M - Total cash dividends paid
€0.00 - Issuance of common stock
€1.46M - Debt repayment
€0.00 - Other financing cash flow
-€213.17K - Net financing cash flow
€1.25M - Foreign exchange effects
-€252.01K - Net change in cash
-€54.73M - Cash at end of period
€63.71M - Free cash flow
-€77.37M
Balance sheet
- Cash and cash equivalents
€63.71M - Cash and short-term investments
€172.53M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€3.39M - Total current assets
€175.92M - Property, plant & equipment
€17.60M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€1.73M - Other non-current assets
€5.18K - Total non-current assets
€19.33M - Total assets
€195.25M - Accounts payable
€2.87M - Short-term debt
€5.33M - Other current liabilities
€7.39M - Total current liabilities
€67.13M - Long-term debt
€30.24M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€653.32K - Total non-current liabilities
€194.28M - Total liabilities
€261.41M - Common stock
€5.18K - Retained earnings
-€513.47M - Other equity
-€37.97K - Total equity
-€66.16M - Total liabilities and shareholders' equity
€195.25M
Company information
- Market capitalization
€230.12M - Employees
112 - Enterprise Value
€229.12M
Company ratios
- Gross margin
-
96.3% Much better than peer group: -274.3% - EBITDA margin
-
-353.6% Much better than peer group: -2,645.2% - EBIT margin
-
-380.0% Much better than peer group: -7,037.0% - EBT margin
-
-311.9% Much better than peer group: -218,760.9% - Net margin
-
-311.9% Much better than peer group: -2,673.4% - ROE
-
98.4% Much better than peer group: -224.5% - ROA
-
-33.3% Much better than peer group: -241.5% - Asset turnover
-
10.7% Much worse than peer group: 102.0% - FCF margin
-
-377.8% Much better than peer group: -15,129.2% - FCF yield
-34.3% - Efficiency ratio
453.6% - Net sales per employee
-
€186.27K - Net income per employee
-
-€580.97K